首页> 美国卫生研究院文献>Taylor Francis Open Select >Efficacy and safety of abatacept for patients with Sjögrens syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjögrens syndrome Endocrinopathy (ROSE) trial—an open-label one-year prospective study—Interim analysis of 32 patients for 24 weeks

【2h】

Efficacy and safety of abatacept for patients with Sjögrens syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjögrens syndrome Endocrinopathy (ROSE) trial—an open-label one-year prospective study—Interim analysis of 32 patients for 24 weeks

机译：阿巴西普对类风湿性关节炎干燥综合征患者的疗效和安全性：类风湿性关节炎Orencia试验用于干燥综合征的内分泌病（ROSE）试验（一项开放性前瞻性前瞻性研究）对32例患者进行了为期24周的中期分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveTo assess the efficacy and safety of abatacept for secondary Sjögren's syndrome (SS) associated with rheumatoid arthritis (RA).

机译：目的评估阿巴西普治疗类风湿关节炎（RA）继发性干燥综合征（SS）的疗效和安全性。

著录项

期刊名称 Taylor Francis Open Select
作者
Hiroto Tsuboi; Isao Matsumoto; Shinya Hagiwara; Tomoya Hirota; Hiroyuki Takahashi; Hiroshi Ebe; Masahiro Yokosawa; Chihiro Hagiya; Hiromitsu Asashima; Chinatsu Takai; Haruka Miki; Naoto Umeda; Yuya Kondo; Hiroshi Ogishima; Takeshi Suzuki; Shintaro Hirata; Kazuyoshi Saito; Yoshiya Tanaka; Yoshiro Horai; Hideki Nakamura; Atsushi Kawakami; Takayuki Sumida;
展开▼
作者单位

展开▼
年(卷),期 -1(25),2
年度 -1
页码 187–193
总页数 7
原文格式 PDF
正文语种
中图分类
关键词
Sjögrens syndrome Rheumatoid arthritis Abatacept;

机译：干燥综合征;类风湿关节炎;阿巴西普;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy (ROSE) trial an open-label, one-year, prospective study Interim analysis of 32 patients for 24 weeks [J] . Tsuboi Hiroto, Matsumoto Isao, Hagiwara Shinya, Modern rheumatology . 2015,第2期

机译：阿巴西普对类风湿性关节炎干燥综合征患者的疗效和安全性：类风湿性关节炎和Orencia试验用于干燥综合征的内分泌病（ROSE）试验为期一年，前瞻性开放性研究32位患者进行了为期24周的中期分析
2. Effectiveness of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy) trial [J] . Tsuboi Hiroto, Matsumoto Isao, Hagiwara Shinya, Modern rheumatology . 2016,第6期

机译：阿巴西普对类风湿关节炎干燥综合征患者的疗效。一项开放性，多中心，为期一年的前瞻性研究：ROSE（类风湿关节炎与针对Sjogren综合征内分泌病的Orencia试验）
3. ACPA-positive primary Sj?gren's syndrome: true primary or rheumatoid arthritis-associated Sj?gren's syndrome? [J] . E Bergé, F Desmoulins, J E Gottenberg, RMD Open . 2015,第1期

机译：ACPA阳性原发性干燥综合征：真正的原发性或类风湿关节炎相关性干燥综合征吗？
4. Predicting lymphoma outcomes and risk factors in patients with primary Sjögren’s Syndrome using gradient boosting tree ensembles [C] . Vasileios C. Pezoulas, Themis P. Exarchos, Athanasios G. Tzioufas, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2019

机译：使用梯度增强树组合预测原发性干燥综合征患者的淋巴瘤结局和危险因素
5. Detection of inflammatory cytokines in Sjögren's syndrome patients using a novel salivary collection device [D] . Aljanobi, Hawra Ali. 2017

机译：使用新型唾液收集装置检测干燥综合征患者的炎性细胞因子
6. Extended report: ACPA-positive primary Sjögrens syndrome: true primary or rheumatoid arthritis-associated Sjögrens syndrome? [O] . J Payet, R Belkhir, J E Gottenberg, 2015

机译：扩展报告：ACPA阳性原发性干燥综合征：真正的原发性或类风湿关节炎相关性干燥综合征？
7. Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial—an open-label, one-year, prospective study—Interim analysis of 32 patients for 24 weeks [O] . Hiroto Tsuboi, Isao Matsumoto, Shinya Hagiwara, 2014

机译：与类风湿性关节炎患者的患者ABATACEPT的疗效和安全性：随着ORENCIA的综合征内分泌术（玫瑰）试验 - 一种开放标签，一年，前瞻性研究 - 32例患者24周

Efficacy and safety of abatacept for patients with Sjögrens syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjögrens syndrome Endocrinopathy (ROSE) trial—an open-label one-year prospective study—Interim analysis of 32 patients for 24 weeks

摘要

著录项

相似文献

相关主题

期刊订阅